A Double-blind, Randomised, Placebo-controlled Phase I Trial to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Topical Doses of GZ21T in Healthy Volunteers
Latest Information Update: 02 Feb 2026
At a glance
- Drugs GZ 17-6.02 (Primary)
- Indications Actinic keratosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genzada Pharmaceuticals
Most Recent Events
- 28 Jan 2026 Status changed from recruiting to completed.
- 28 Mar 2025 New trial record